سعر ايمجاليتي 120مجم/مل قلم معبأ 2025

Emgality 120 mg/ml subcutaneous prefilled pen (galcanezumab), Eli Lilly, Egypt.

• Preventive treatment of migraine in adults.Population: AdultsDailyMed / FDA
• Treatment of episodic cluster headache in adults.Population: AdultsDailyMed / FDA

• Most common adverse reactions (≥2% and ≥2% vs placebo): injection site reactions (~18% vs 13% placebo in migraine trials).International label, same product · DailyMed / FDA

• Serious hypersensitivity to galcanezumab-gnlm or any excipient.International label, same product · DailyMed / FDA

• Hypersensitivity (including anaphylaxis/angioedema) can occur days after dosing and may be prolonged. Constipation with serious complications reported. New/worsening hypertension. New/worsening Raynaud phenomenon — discontinue if develops.International label, same product · DailyMed / FDA

• No adequate human data; animal studies at exposures above clinical doses did not show adverse developmental effects. Pregnancy registry available (US).International label, same product · DailyMed / FDA
• No data on presence in human milk or effects on infant/milk production; consider benefits of breastfeeding vs maternal need.International label, same product · DailyMed / FDA

• Galcanezumab: Humanized IgG4 monoclonal antibody that binds CGRP ligand and blocks receptor binding.